Thursday, November 26, 2020
Financing and M&A

Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures

Vesigen Therapeutics launched today with the objective to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9, RNA molecules and other therapeutic proteins, by using a proprietary delivery technology. Leaps by Bayer and Morningside Ventures led the company’s Series A financing with USD 28.5 million and were joined by Linden Lake Ventures and Alexandria Venture Investments.

New modalities, such as gene editing, mRNA replacement, and RNA interference, have huge potential for future therapies and even curative treatments. However, delivery of these modalities to target disease in specific cells and tissues has proven difficult. As more than 80 percent of identified and biologically validated drug targets are located within a human cell, there is a high need for innovative intracellular delivery technology to transport these molecules to the target and unlock the full potential of new therapeutic modalities. Vesigen is developing a novel delivery technology that addresses this hurdle and opens new pathways to transformative treatment options for patients.

“Our mission is to realize the therapeutic potential of many of the new modalities, such as RNA interference, mRNA replacement, and gene editing, that have been used to identify and validate targets, but have proven difficult to translate into functional therapeutics due to delivery barriers,” said Robert Millman, Co-Founder and CEO of Vesigen Therapeutics.

Vesigen is developing drugs based on the proprietary ARRDC1-mediated microvesicles (ARMMs) technology, a class of fusogenic extracellular vesicles that nature evolved to package and deliver communication signals between cells and tissues. ARMMs possess unique properties, making them better suited for producing and delivering therapeutic agents. Vesigen and its scientific founders have demonstrated a wide range of therapeutic payloads can be packaged in ARMMs, including RNA, protein, and gene-editing systems and functionally delivered intracellularly in vitro and in vivo.

The company’s Scientific Advisory Board will include:

  • Quan Lu, PhD, Scientific Co-Founder, Vesigen Therapeutics
  • Stephen Haggarty, PhD, Massachusetts General Hospital
  • Thomas Reh, PhD, University of Washington
13 thoughts on “Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures
  1. Pingback: Immediate Edge
  2. Pingback: Plumber Near Me
  3. Pingback: online cvv shop

Leave a Reply

Your email address will not be published.